

Rare Diseases and Congenital Heart Diseases: A Call for Genetic Insight

To the Editor,

February 28 is celebrated all over the world as Rare Disease Day to increase the awareness of rare diseases and to accelerate the diagnosis and treatment of these diseases. If a disease prevalence is less than 1 in 2000, it is considered rare in Europe. In the USA, a disease is considered rare if it is 1 in 20 000. Each rare disease may be "rare" on its own, but collectively there are approximately 300 million people in the world living with a rare disease. In Türkiye, 2.9 to 4.8 million people are living with at least one rare disease, but this number is probably higher due to many undiagnosed cases. Seventy percent of these rare diseases are diagnosed in children.

Congenital heart disease (CHD) can be the first presenting sign of a rare disease. The dysmorphic features may not be present, or the disease can have very broad phenotypic features, as in DiGeorge syndrome (22q11.2 deletion syndrome), which is detected in approximately 2% of all patients with CHD¹ and in 13% of patients with specific cardiac malformations.

Referral to a geneticist increases the diagnosis rate of infants with CHD by 7-13%, after excluding Down syndrome.² Genetic counseling can have an impact on diagnostic, prognostic, and therapeutic decision-making. Patients with certain types of syndromes have different survival outcomes after surgery, and this is important for planning the right treatment plan as part of personalized medicine.³ In Noonan syndrome, for example, there are bleeding tendencies and lymphatic anomalies which can affect cardiac care if not detected before. In Turner syndrome, 50% of the patients have CHD, most commonly bicuspid aortic valve and coarctation of the aorta. There may be associated coronary artery anomalies not detected by transthoracic echocardiography. Kabuki syndrome, Loeys–Dietz syndrome, Alagille syndrome, and Holt–Oram syndrome are other examples of rare diseases associated with CHD.

Patients with CHD now reach adulthood and have an increased risk of having infants with CHD.⁴ If we know the genetic etiology of CHD, we know the inheritance pattern and can give accurate family planning advice. This means healthier children and a healthier society.

Declaration of Interests: The author have no conflict of interests to declare.

Funding: The author declare that this study has received no financial support.

LETTER TO THE EDITOR

Hande Kaymakçalan Çelebiler 

Department of Neurosurgery, Yale
University, NewHaven, CT, USA

Corresponding author:

Hande Kaymakçalan Çelebiler
✉ doctorhande@yahoo.com

Cite this article as: Kaymakçalan
Çelebiler H. Rare diseases and
congenital heart diseases: A call for
genetic insight. *Anatol J Cardiol.*
2025;XX(X):1-2.

DOI:10.14744/AnatolJCardiol.2025.5297



Copyright©Author(s) - Available online at anatoljcardiol.com.
Content of this journal is licensed under a Creative Commons Attribution-NonCommercial
4.0 International License.

REFERENCES

1. Agergaard P, Olesen C, Østergaard JR, Christiansen M, Sørensen KM. The prevalence of chromosome 22q11.2 deletions in 2,478 children with cardiovascular malformations. A population-based study. *Am J Med Genet A*. 2012;158A(3):498-508. [\[CrossRef\]](#)
2. Geddes GC, Earing MG. Genetic evaluation of patients with congenital heart disease. *Curr Opin Pediatr*. 2018;30(6):707-713. [\[CrossRef\]](#)
3. Morales-Demori R. Congenital heart disease and cardiac procedural outcomes in patients with trisomy 21 and Turner syndrome. *Congenit Heart Dis*. 2017;12(6):820-827. [\[CrossRef\]](#)
4. Blue GM, Kirk EP, Giannoulatou E, et al. Advances in the genetics of congenital heart disease: a clinician's guide. *J Am Coll Cardiol*. 2017;69(7):859-870. [\[CrossRef\]](#)